Blood Processing Devices MarketSize, Share & Industry Analysis, 2026-2034By ProductBy ApplicationBy End-userBy TechnologyBy Usage
Full title & scope — all 5 axes with their segments
Blood Processing Devices Market Size, Share & Industry Analysis, By Product (Blood Bags, Blood Collection Tubes, Needles & Syringes, Blood Collection Systems/Monitors, Lancets), By Application (Blood Transfusion, Therapeutic Applications, Diagnostic and Research), By End-user (Hospitals, Ambulatory Surgical Centers, & Nursing Homes, Diagnostic & Pathology Laboratories, Blood Banks, Others), By Technology (Automated/Apheresis-Based Systems, Semi-Automated Systems, Manual/Gravity-Based Systems), By Usage (Single-Use/Disposable, Reusable/Durable), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By ProductBlood Bags · Blood Collection Tubes · Needles & Syringes
- 02By ApplicationBlood Transfusion · Therapeutic Applications · Diagnostic and Research
- 03By End-userHospitals, Ambulatory Surgical Centers, & Nursing Homes · Diagnostic & Pathology Laboratories · Blood Banks
- 04By TechnologyAutomated/Apheresis-Based Systems · Semi-Automated Systems · Manual/Gravity-Based Systems
- 05By UsageSingle-Use/Disposable · Reusable/Durable
- 06By Region
Market Analysis & Outlook
Blood processing devices comprise the equipment and consumables used to collect, separate, store, and monitor human blood and its components, including collection tubes, needles and syringes, collection bags, automated collection and monitoring systems, and lancets. Buyers span hospitals, ambulatory surgical centers and nursing homes, diagnostic and pathology laboratories, and blood banks that manage donor collection, component separation, and inventory for transfusion, therapeutic, and diagnostic use.
The global blood processing devices market stood at USD 54.2 billion in 2025. A forecast-period rate of 7.01% takes it to USD 99.2 billion by 2034, and the study reports every year in between, passing USD 38 billion in 2020, USD 50.3 billion in 2024, USD 57.7 billion in 2026 and USD 75.6 billion in 2030.
On the product axis, growth rates run from 5.07% for Needles & Syringes up to 11.81% for Blood Collection Systems/Monitors. Blood Bags carries the volume: USD 16.26 billion and 30% of revenue in 2025, USD 26.78 billion and 27% in 2034. Share moves toward Blood Collection Systems/Monitors and away from Blood Bags, Blood Collection Tubes, Needles & Syringes and Lancets, though no line shrinks in revenue terms.
By application, Blood Transfusion accounts for 55% of 2025 revenue at USD 29.81 billion, reaching USD 49.6 billion and 50% by 2034. Diagnostic and Research grows faster at 8.31% against 5.82%, moving from 25% of revenue to 28% by 2034. This axis divides the same revenue as the product split instead of adding to it, so the two are read together and never summed.
The regional order runs from North America at 37% of 2025 revenue down to Middle East and Africa at 6%. North America is worth USD 20.05 billion in 2025 and USD 33.73 billion in 2034; Europe, second at 26%, moves from USD 14.09 billion to USD 23.81 billion. Share shifts toward Asia Pacific over the forecast period, so the regional split repays a close reading.
Coverage extends to five regions, five product lines and five segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies, short of a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global blood processing devices market moves from USD 38 billion in 2020 to USD 54.2 billion in 2025 and USD 99.2 billion by 2034, the forecast period compounding at 7.01% a year.
- 30% of 2025 revenue sits in Blood Bags (USD 16.26 billion) and it remains the largest product line in 2034 at USD 26.78 billion and 27%.
- Blood Collection Systems/Monitors is the fastest-growing line at 11.81%, lifting its share from 16% in 2025 to 24% in 2034 and its revenue from USD 8.67 billion to USD 23.81 billion.
- Against a base case of USD 99.2 billion in 2034, the study also reports a bear case at USD 90.97 billion and a bull case at USD 108.13 billion, with the assumptions behind each set out separately.
- The largest region is North America, generating USD 20.05 billion in 2025 (37% of the global total) and USD 33.73 billion by 2034, ahead of Europe at 26%.
- The United States accounts for 85% of North America in the base year, worth USD 17.04 billion in 2025 and reaching USD 28.67 billion by 2034, the worked country example carried through that region's chapters.
- Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.
Market Trends
Revenue Share, By By Product
Base year 2025Blood Bags leads with 30.0% of by product segment revenue.
Share of by product segment revenue, most recent base year.
Read across the forecast period, the global blood processing devices market shows movement in three places: product composition, regional weight, and the 7.01% rate applied to the whole.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
Blood Collection Systems/Monitors grows at more than twice the pace of Needles & Syringes. Between 2026 and 2034, 11.81% growth in Blood Collection Systems/Monitors against 5.07% in Needles & Syringes pulls the product mix apart. Shares follow: 16% to 24% for Blood Collection Systems/Monitors, 20% to 17% for Needles & Syringes. The revenue figures behind that are USD 8.67 billion to USD 23.81 billion and USD 10.84 billion to USD 16.86 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.
Asia Pacific gain regional share. Asia Pacific moves from 24% of revenue in 2025 to 29% in 2034, worth USD 13.01 billion rising to USD 28.77 billion. Against that, North America at 37% moving to 34%, Europe at 26% moving to 24%, Latin America at 7% moving to 7%, Middle East and Africa at 6% moving to 6%, a fall in share, not in revenue. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
Fifteen years without a discontinuity. Year by year the total runs USD 38 billion in 2020, USD 50.3 billion in 2024, USD 54.2 billion in 2025, USD 57.7 billion in 2026, USD 75.6 billion in 2030 and USD 99.2 billion in 2034. Against 7.37% through the historical period, the 7.01% forecast rate is a continuation; no year in the series interrupts it. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the product and regional sections come in.
Market Growth Factors
Blood Collection Systems/Monitors carries the market's growth rate
Market Drivers
3- 01Blood Collection Systems/Monitors carries the market's growth rate
At 11.81% against a market rate of 7.01%, Blood Collection Systems/Monitors is the line pulling the average up: USD 8.67 billion to USD 23.81 billion, and 16% of revenue to 24%. Set against 5.07% at the other end of the axis, this is the line that decides whether the market's 7.01% holds. A portfolio weighted away from it tracks below the market even in a market growing everywhere.
- 02North America carries 37% of the base and keeps growing
North America is the largest region at USD 20.05 billion in 2025, 37% of global revenue, and reaches USD 33.73 billion by 2034 while holding 34%. Europe is next at 26% of revenue, USD 14.09 billion in 2025 and USD 23.81 billion in 2034. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03The base has grown every year since 2020
The historical period compounded at 7.37%; USD 38 billion in 2020, USD 50.3 billion in 2024 and USD 54.2 billion in 2025. From there the forecast carries 7.01% through to USD 99.2 billion in 2034. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 7.01% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising global blood donation and transfusion volumes | High | +14 | High | High | High |
| 2 | Expansion of automated and apheresis-based collection technology | Medium-High | +10.5 | Medium | High | High |
| 3 | Growth in therapeutic and research use of blood-derived products | Medium-High | +8 | Medium | Medium | High |
| 4 | Expanding blood bank and laboratory infrastructure in emerging markets | Medium | +7 | Medium | Medium | Medium |
| 5 | Tightening blood safety and traceability regulation | Medium | +5.5 | Medium | Low | Low |
| 6 | Others | Low | +3 | Low | Low | Low |
| Total | +48 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Tender-based procurement pricing pressure | Medium | −2 | Medium | Medium | Medium |
| 2 | Slower device replacement cycles in budget-constrained public health systems | Medium | −1 | Low | Medium | Medium |
| Total | −3 | |||||
Drivers contribute 48 Billion and restraints remove 3 Billion, a net 45 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Growth in the global blood processing devices market comes from three measurable sources over 2026-2034: the market's own compounding at 7.01%, the share gained by faster-growing product lines, and expansion in the regions taking a larger part of global revenue.
Restraining Factors
Downside case: USD 90.97 billion by 2034, against USD 99.2 billion in the base case
Market Restraints
2- 01Downside case: USD 90.97 billion by 2034, against USD 99.2 billion in the base case
The study's downside path assumes slower replacement of manual collection equipment and tighter public health procurement budgets that delay device upgrades in cost-constrained markets, and ends 2034 at USD 90.97 billion against the USD 99.2 billion base case, the same USD 54.2 billion base year, a slower forecast period.
- 02The largest line is not the fastest
With 30% of 2025 revenue (USD 16.26 billion) Blood Bags is where most of the market sits, and it grows at only 5.75% against the market's 7.01%. Revenue still reaches USD 26.78 billion by 2034 and share still falls to 27%: a drag on the average, not a decline.
Market Opportunities
What the bull case turns on
Market Opportunities
2- 01What the bull case turns on
The upside path assumes faster hospital and blood bank adoption of automated and apheresis-based collection systems combined with sustained growth in donation and therapeutic blood product volumes. It ends 2034 at USD 108.13 billion against a USD 99.2 billion base case, off the same USD 54.2 billion base year.
- 02Blood Collection Systems/Monitors is where share changes hands
Share on the product axis moves toward Blood Collection Systems/Monitors, from 16% in 2025 to 24% in 2034, on 11.81% growth against the market's 7.01% and revenue rising from USD 8.67 billion to USD 23.81 billion. Taking position there does not require displacing whoever holds Blood Bags, which is the harder and more expensive fight.
Market Challenges
One product line carries the market
Market Challenges
2- 01One product line carries the market
Blood Bags is 30% of 2025 revenue at USD 16.26 billion and still 27% at USD 26.78 billion in 2034. That concentration means the market's own forecast is, to a large extent, a forecast for one product line.
- 02Single-country exposure in North America
85% of the leading region is one country: the United States, at USD 17.04 billion against North America's USD 20.05 billion in 2025, and USD 28.67 billion by 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
5 axesThe global blood processing devices market is cut five ways: by product, application, end-user, technology and usage. Each axis cuts the same total revenue along a different commercial dimension, so the splits are alternative views of one market, not additions to it.
Five product lines are reported. One of them takes share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Product · 5 segments
Blood Bags Led by Product in 2025, with Blood Collection Systems/Monitors Growing Fastest
- Largest Blood Bags · 30%
- Fastest Blood Collection Systems/Monitors · 11.8%
- Moves most Blood Collection Systems/Monitors · +8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Blood Bags | $16.26B | 30% | $26.78B | 27%-3 | 5.8% |
| Blood Collection Tubes | $14.09B | 26% | $23.81B | 24%-2 | 6% |
| Needles & Syringes | $10.84B | 20% | $16.86B | 17%-3 | 5.1% |
| Blood Collection Systems/Monitors | $8.67B | 16% | $23.81B | 24%+8 | 11.8% |
| Lancets | $4.34B | 8% | $7.94B | 8% | 7% |
Blood Bags lead because they are a repeated, disposable purchase at the center of every collection and storage step blood banks and hospitals perform, so volume alone keeps demand steady. Blood Collection Systems and Monitors grow fastest as collection sites replace manual handling with automated tracking that cuts contamination risk and speeds donor throughput. By 2034 Blood Bags is still ahead, making this a shift in weight, not a change of leader. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Application · 3 segments
Blood Transfusion Led by Application in 2025, with Diagnostic and Research Growing Fastest
- Largest Blood Transfusion · 55%
- Fastest Diagnostic and Research · 8.3%
- Moves most Blood Transfusion · -5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Blood Transfusion | $29.81B | 55% | $49.60B | 50%-5 | 5.8% |
| Therapeutic Applications | $10.84B | 20% | $21.82B | 22%+2 | 8.1% |
| Diagnostic and Research | $13.55B | 25% | $27.78B | 28%+3 | 8.3% |
Blood Transfusion leads because routine surgical, trauma, and obstetric care depend on a steady transfusion supply that hospitals and blood banks must maintain regardless of economic conditions. Diagnostic and Research applications grow fastest as laboratories expand testing panels and research institutions scale up work with blood-derived samples, pulling more collection and processing equipment into that channel. By 2034 Blood Transfusion is still ahead, making this a shift in weight, not a change of leader.
By End-user · 4 segments
Hospitals, Ambulatory Surgical Centers, & Nursing Homes Held the Dominant Share of the End-user Segment in 2025
- Largest Hospitals, Ambulatory Surgical Centers, & Nursing Homes · 45%
- Fastest Diagnostic & Pathology Laboratories · 8%
- Moves most Hospitals, Ambulatory Surgical Centers, & Nursing Homes · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals, Ambulatory Surgical Centers, & Nursing Homes | $24.39B | 45% | $41.66B | 42%-3 | 6.1% |
| Diagnostic & Pathology Laboratories | $11.92B | 22% | $23.81B | 24%+2 | 8% |
| Blood Banks | $13.55B | 25% | $25.79B | 26%+1 | 7.4% |
| Others | $4.34B | 8% | $7.94B | 8% | 6.9% |
Hospitals, Ambulatory Surgical Centers, and Nursing Homes lead because they run the highest volume of collection, transfusion, and inventory activity of any buyer type in this market. Diagnostic and Pathology Laboratories grow fastest as expanding test menus and higher sample throughput push these facilities to add collection and processing capacity faster than hospital networks are expanding theirs. The order does not change: Hospitals, Ambulatory Surgical Centers, & Nursing Homes is still largest in 2034, and what moves is how much it holds.
By Technology · 3 segments
Automated/Apheresis-Based Systems Outpaces the Axis While Semi-Automated Systems Holds the Largest Share
- Largest Semi-Automated Systems · 35%
- Fastest Automated/Apheresis-Based Systems · 10.4%
- Moves most Manual/Gravity-Based Systems · -11 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Automated/Apheresis-Based Systems | $16.26B | 30% | $39.68B | 40%+10 | 10.4% |
| Semi-Automated Systems | $18.97B | 35% | $35.71B | 36%+1 | 7.3% |
| Manual/Gravity-Based Systems | $18.97B | 35% | $23.81B | 24%-11 | 2.6% |
Semi-Automated Systems and Manual, Gravity-Based Systems together still cover most collection sites because many blood banks and smaller hospitals have not yet replaced existing equipment. Automated and Apheresis-Based Systems grow fastest as larger blood banks and hospital networks prioritize component-specific collection and the traceability that automated platforms provide over older manual methods. Leadership changes hands: Automated/Apheresis-Based Systems is the largest line by 2034, not Semi-Automated Systems.
By Usage · 2 segments
Scale in Single-Use/Disposable and Growth in Reusable/Durable Define the Usage Axis
- Largest Single-Use/Disposable · 78%
- Fastest Reusable/Durable · 8%
- Moves most Single-Use/Disposable · -2 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Single-Use/Disposable | $42.28B | 78% | $75.39B | 76%-2 | 6.6% |
| Reusable/Durable | $11.92B | 22% | $23.81B | 24%+2 | 8% |
Single-Use, Disposable products lead because infection-control practice across collection and transfusion settings favors discarding contact items after one use rather than reprocessing them. Reusable, Durable equipment grows faster as facilities invest in longer-life collection and monitoring hardware that pairs with single-use consumables rather than replacing the whole system each cycle. Reusable/Durable grows fastest here, so its share rises while Single-Use/Disposable gives ground. By 2034 Single-Use/Disposable is still ahead, making this a shift in weight, not a change of leader.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 3 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 1 of 5
- 2025 share 37%
- By 2034 34%
- Revenue $20.05B → $33.73B
In North America, 37% of global revenue puts 2025 at USD 20.05 billion and reaches USD 33.73 billion by 2034. Among the five regions it ranks first by revenue in both years.
By 2034 the share stands at 34%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
The product mix reported at global level applies here, with Blood Bags the largest line at 30% of 2025 revenue and Blood Collection Systems/Monitors the fastest-growing at 11.81%. Revenue for North America is broken out by every segmentation axis and by country in the full report.
United States
Sets the pace for North America at 85% of it, growing 1.7×.
- In region 1 of 2
- Of region 85%
- Of global 31.4%
- Revenue $17.04B → $28.67B
The United States is the largest market within North America, generating USD 17.04 billion in 2025 and projected to reach USD 28.67 billion by 2034. At 85% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. The region itself runs USD 20.05 billion to USD 33.73 billion over the same period, and this is the market carrying the country-level detail in the full report.
The product pattern in the United States is the global one: 30% of 2025 revenue in Blood Bags, 27% by 2034, against 11.81% growth in Blood Collection Systems/Monitors taking it from 16% to 24%. With 85% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The United States carries its own product breakdown in the full report.
Blood processing devices sold in the United States are regulated by the Food and Drug Administration's Center for Devices and Radiological Health under the Federal Food, Drug, and Cosmetic Act. Most blood collection, separation, and apheresis systems are classified as moderate to high risk and require premarket clearance or approval before a manufacturer can market them, with devices tied directly to blood establishment operations often subject to the stricter biologics license pathway overseen jointly with the Center for Biologics Evaluation and Research. Manufacturers must operate under the Quality System Regulation, register their facilities, and list their devices. Labelling must disclose intended use, storage conditions, and compatibility with blood bags and anticoagulant solutions, and conformity with recognized consensus standards for blood collection and processing equipment is expected as part of a complete submission.
Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US) are the suppliers covered in the United States. Two different problems sit on the same axis: holding Blood Bags at 30% of 2025 revenue, and taking Blood Collection Systems/Monitors while it grows at 11.81%. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 1.7×.
- In region 2 of 2
- Of region 15%
- Of global 5.6%
- Revenue $3.01B → $5.06B
Canada is sized at USD 3.01 billion in 2025, rising to USD 5.06 billion by 2034; 5.6% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Europe Market Analysis
The 2nd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 2 of 5
- 2025 share 26%
- By 2034 24%
- Revenue $14.09B → $23.81B
Europe holds 26% of the global blood processing devices market in 2025, worth USD 14.09 billion on the way to USD 23.81 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.
By 2034 the share stands at 24%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Segment composition follows the global pattern: Blood Bags largest at 30% of 2025 revenue, Blood Collection Systems/Monitors fastest at 11.81%. Per-axis and per-country detail for Europe sits in the full report.
Germany
The largest market in Europe, growing 1.7×.
- In region 1 of 3
- Of region 30%
- Of global 7.8%
- Revenue $4.23B → $7.14B
Germany is the largest market within Europe, generating USD 4.23 billion in 2025 and projected to reach USD 7.14 billion by 2034. 30% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 14.09 billion to USD 23.81 billion over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is Blood Bags at 30% of 2025 revenue, easing to 27% by 2034, and the fastest is Blood Collection Systems/Monitors at 11.81%, from 16% to 24%. Since 30% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Germany carries its own product breakdown in the full report.
In Germany, blood processing devices fall under the European Union Medical Device Regulation, enforced domestically through the Medical Devices Act and overseen by the Federal Institute for Drugs and Medical Devices alongside notified bodies that conduct conformity assessment. Devices used in blood collection, separation, and component processing are generally classified in the higher risk tiers given their contact with blood destined for transfusion, requiring a technical file, clinical evaluation, and a CE mark before sale. Manufacturers must also meet the German Transfusion Act's requirements where a device interfaces with blood establishment quality systems. Labelling must be provided in German, state intended use and handling conditions clearly, and conformity with harmonized standards covering sterility, biocompatibility, and mechanical safety is a precondition for market access.
In Germany the field is Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US). The commercially relevant division is 30% of 2025 revenue in Blood Bags, where the volume is, against 11.81% growth in Blood Collection Systems/Monitors, where share moves. That makes Europe a 26% share of 2025 global revenue, USD 14.09 billion rising to USD 23.81 billion, for any supplier deciding where to concentrate.
United Kingdom
2nd-largest in Europe, growing 1.7×.
- In region 2 of 3
- Of region 25%
- Of global 6.5%
- Revenue $3.52B → $5.95B
6.5% of global revenue is generated in the United Kingdom; USD 3.52 billion in 2025, reaching USD 5.95 billion in 2034, and 25% of Europe.
France
3rd-largest in Europe, growing 1.7×.
- In region 3 of 3
- Of region 20%
- Of global 5.2%
- Revenue $2.82B → $4.76B
Within Europe, France accounts for 20% of regional revenue and 5.2% of the global total, worth USD 2.82 billion in 2025 and USD 4.76 billion by 2034.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 5 points of share by 2034, while revenue still grows 2.2×.
- Rank 3 of 5
- 2025 share 24%
- By 2034 29%
- Revenue $13.01B → $28.77B
Asia Pacific holds 24% of the global blood processing devices market in 2025, worth USD 13.01 billion with USD 28.77 billion projected for 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.
Its share rises to 29% over the forecast period, so the region grows faster than the market's 7.01% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Segment composition follows the global pattern: Blood Bags largest at 30% of 2025 revenue, Blood Collection Systems/Monitors fastest at 11.81%. Per-axis and per-country detail for Asia Pacific sits in the full report.
China
The largest market in Asia Pacific, growing 2.2×.
- In region 1 of 3
- Of region 35%
- Of global 8.4%
- Revenue $4.55B → $10.07B
China is the largest market within Asia Pacific, generating USD 4.55 billion in 2025 and projected to reach USD 10.07 billion by 2034. It accounts for 35% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 13.01 billion to USD 28.77 billion over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is Blood Bags at 30% of 2025 revenue, easing to 27% by 2034, and the fastest is Blood Collection Systems/Monitors at 11.81%, from 16% to 24%. Since 35% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports China by product separately.
China regulates blood processing devices through the National Medical Products Administration under its medical device classification framework. Devices that come into direct contact with blood intended for transfusion or component separation are typically placed in the higher classification categories, requiring registration approval before domestic sale and, for many products, local clinical evaluation or trial data specific to Chinese patients. Manufacturers, including those importing from abroad, must appoint a domestic agent and demonstrate compliance with national standards covering material safety, sterilization, and performance. Labelling and instructions must appear in Chinese and specify intended use, storage, and compatibility requirements. Facilities producing these devices must also operate under a quality management system aligned with national good manufacturing practice requirements before registration can be granted.
Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US) are the suppliers covered in China. Volume sits in Blood Bags at 30% of 2025 revenue; movement sits in Blood Collection Systems/Monitors at 11.81% growth. That makes Asia Pacific a 24% share of 2025 global revenue, USD 13.01 billion rising to USD 28.77 billion, for any supplier deciding where to concentrate.
Japan
2nd-largest in Asia Pacific, growing 1.9×.
- In region 2 of 3
- Of region 25%
- Of global 6%
- Revenue $3.25B → $6.33B
Within Asia Pacific, Japan accounts for 25% of regional revenue and 6% of the global total, worth USD 3.25 billion in 2025 and USD 6.33 billion by 2034.
India
3rd-largest in Asia Pacific, growing 2.7×.
- In region 3 of 3
- Of region 15%
- Of global 3.6%
- Revenue $1.95B → $5.18B
3.6% of global revenue is generated in India; USD 1.95 billion in 2025, reaching USD 5.18 billion in 2034, and 15% of Asia Pacific.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 1.8×.
- Rank 4 of 5
- 2025 share 7%
- By 2034 7%
- Revenue $3.79B → $6.94B
USD 3.79 billion of 2025 revenue is generated in Latin America, 7% of the global blood processing devices market with USD 6.94 billion projected for 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.
By 2034 the share stands at 7%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Within the region the product split tracks the global one; 30% of 2025 revenue in Blood Bags, fastest growth of 11.81% in Blood Collection Systems/Monitors. Per-axis and per-country detail for Latin America sits in the full report.
Brazil
The largest market in Latin America, growing 1.8×.
- In region 1 of 2
- Of region 45%
- Of global 3.2%
- Revenue $1.71B → $3.12B
Brazil is the largest market within Latin America, generating USD 1.71 billion in 2025 and projected to reach USD 3.12 billion by 2034. It accounts for 45% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 3.79 billion in 2025 and USD 6.94 billion in 2034, it is the country the full report breaks out in detail.
Brazil buys along the same lines as the market globally; Blood Bags first at 30% of 2025 revenue and 27% in 2034, Blood Collection Systems/Monitors fastest at 11.81% on a share moving from 16% to 24%. Because the country carries 45% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by product for Brazil is reported separately in the full report.
Brazil's health surveillance agency, ANVISA, governs the approval and marketing of blood processing devices under its medical device regulatory framework. Products used for blood collection, separation, or component processing are generally classified according to the risk they pose to donors and recipients, with higher risk categories requiring a full registration dossier that includes technical and safety documentation before a device can be sold. Manufacturing sites, whether domestic or foreign, must demonstrate compliance with Brazil's good manufacturing practice certification, which ANVISA verifies through inspection or recognition of an equivalent foreign audit. Labelling must be presented in Portuguese and include intended use, handling instructions, and storage conditions, and conformity with applicable national and international standards for blood-contact equipment is expected throughout the registration process.
In Brazil the field is Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US). Volume sits in Blood Bags at 30% of 2025 revenue; movement sits in Blood Collection Systems/Monitors at 11.81% growth. A supplier weighted toward Latin America is competing over a base of USD 3.79 billion in 2025 reaching USD 6.94 billion by 2034, 7% of global revenue at the start of that period.
Mexico
2nd-largest in Latin America, growing 1.8×.
- In region 2 of 2
- Of region 30%
- Of global 2.1%
- Revenue $1.14B → $2.08B
Within Latin America, Mexico accounts for 30% of regional revenue and 2.1% of the global total, worth USD 1.14 billion in 2025 and USD 2.08 billion by 2034.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 1.8×.
- Rank 5 of 5
- 2025 share 6%
- By 2034 6%
- Revenue $3.25B → $5.95B
USD 3.25 billion of 2025 revenue is generated in Middle East and Africa, 6% of the global blood processing devices market on the way to USD 5.95 billion by 2034. Among the five regions it ranks fifth by revenue in both years.
6% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
The product mix reported at global level applies here, with Blood Bags the largest line at 30% of 2025 revenue and Blood Collection Systems/Monitors the fastest-growing at 11.81%. The full report breaks Middle East and Africa out along every axis and by country.
Saudi Arabia
The largest market in Middle East and Africa, growing 1.8×.
- In region 1 of 2
- Of region 35%
- Of global 2.1%
- Revenue $1.14B → $2.08B
The largest single market in Middle East and Africa is Saudi Arabia, at USD 1.14 billion in 2025 and USD 2.08 billion in 2034. At 35% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Set against USD 3.25 billion and USD 5.95 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Demand in Saudi Arabia follows the product mix reported at global level: Blood Bags is the largest line at 30% of 2025 revenue, moving to 27% by 2034, while Blood Collection Systems/Monitors grows fastest at 11.81% and takes its share from 16% to 24%. Because the country carries 35% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Saudi Arabia carries its own product breakdown in the full report.
The Saudi Food and Drug Authority regulates blood processing devices in Saudi Arabia through its medical device marketing authorization system, which draws on the Gulf-wide harmonized framework for device classification and conformity assessment. Devices used in blood collection or component separation are assessed according to risk level, and manufacturers must register both the device and the local authorized representative before distribution is permitted. Conformity with recognized international standards for blood-contact equipment, sterility, and performance is required as supporting evidence within the registration file. Labelling must be provided in Arabic alongside English, state intended use and storage conditions plainly, and importers must maintain traceability records so that any safety concern raised after market entry can be tracked back to the responsible supplier.
Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US) are the suppliers covered in Saudi Arabia. Blood Bags, at 30% of 2025 revenue, is where the volume sits, and Blood Collection Systems/Monitors, growing at 11.81%, is where position changes hands over the forecast period. A supplier weighted toward Middle East and Africa is competing over a base of USD 3.25 billion in 2025 reaching USD 5.95 billion by 2034, 6% of global revenue at the start of that period.
South Africa
2nd-largest in Middle East and Africa, growing 1.8×.
- In region 2 of 2
- Of region 25%
- Of global 1.5%
- Revenue $0.81B → $1.49B
1.5% of global revenue is generated in South Africa; USD 0.81 billion in 2025, reaching USD 1.49 billion in 2034, and 25% of Middle East and Africa.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product, Application, End-User, Technology, Usage, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Position on the Product Axis Decides Competitive Standing
Suppliers in scope: Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Haemonetics Corporation (US).
Competition follows the product split, not the regional one. 30% of 2025 revenue, worth USD 16.26 billion, is in Blood Bags, still 27% of the total in 2034; that is the position least likely to change hands. Share moves in Blood Collection Systems/Monitors, growing 11.81% against 5.07% for Needles & Syringes. The two rarely sit with the same supplier, and that is the reason a USD 54.2 billion market is not already consolidated.
Scale in blood bag and collection tube manufacturing sets the largest suppliers apart, since consistent sterile production at high volume is what hospital and blood bank contracts require. Regulatory and approval experience across multiple jurisdictions lets the largest players move new collection and monitoring systems into more markets faster than smaller rivals can. Distribution reach into hospital networks and blood banks matters as much as the product itself, and established suppliers use that reach to bundle consumables with equipment. Smaller and regional suppliers compete mainly on price and on close relationships with local blood banks and laboratories rather than on breadth of product line.
Geographic reach is the other axis of competition. North America alone accounts for 37% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 26%.
Per-company profiles, financials, share and development history are in the full report and not here.
List of Key Blood Processing Devices Market Companies Profiled
10 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Abbott (US)
- Biomerieux (France)
- BD(US)
- Bio-Rad Laboratories. Inc (US)
- Danaher (US)
- Grifols S.A (India)
- Thermogenesis Holdings. Inc (US)
- Terumo Corporation (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Haemonetics Corporation (US)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Product, Application, End-user, Technology, Usage), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 10 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Blood Processing Devices Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Blood Processing Devices Market Overview, By Product, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Blood Processing Devices Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Blood Processing Devices Market Overview, By End-user, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Blood Processing Devices Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Blood Processing Devices Market Overview, By Usage, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Blood Processing Devices Market Size — Segment Comparison
Chapter 22.Global Blood Processing Devices Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Blood Processing Devices Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Blood Processing Devices Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Blood Processing Devices Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Blood Processing Devices Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Blood Processing Devices Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Product
5- 01Blood Bags
- 02Blood Collection Tubes
- 03Needles & Syringes
- 04Blood Collection Systems/Monitors
- 05Lancets
By Application
3- 01Blood Transfusion
- 02Therapeutic Applications
- 03Diagnostic and Research
By End-user
4- 01Hospitals, Ambulatory Surgical Centers, & Nursing Homes
- 02Diagnostic & Pathology Laboratories
- 03Blood Banks
- 04Others
By Technology
3- 01Automated/Apheresis-Based Systems
- 02Semi-Automated Systems
- 03Manual/Gravity-Based Systems
By Usage
2- 01Single-Use/Disposable
- 02Reusable/Durable
Segment categories shown for scope reference. See the Summary tab for revenue share by By Product. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The base year size was built upward from blood collection and processing volumes: donor collection episodes, apheresis procedure counts, and blood bag, tube, and needle unit shipments by region, each carried at a realized average selling price drawn from distributor and tender pricing. Automated and semi-automated system counts were sized separately from installed base and replacement cycle data before being priced. The resulting build was checked against disclosed device and consumables revenue from the major listed suppliers named in this report; where a region's bottom-up total sat outside the range implied by those disclosures, the underlying volume or price assumption for that region was revisited and corrected rather than the two figures averaged together.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews target procurement and supply chain managers at hospital networks and blood banks, laboratory directors overseeing sample collection budgets, product and commercial managers at device and consumables suppliers, and regulatory affairs staff who track device clearance and blood safety compliance in each market. Sampling weights North America and Europe, where blood safety programs are most established and disclosure is richest, while extending coverage into Asia Pacific procurement contacts to capture the pace of automation adoption in higher-growth markets. Channel partners and distributors covering smaller hospital and laboratory accounts are included to reflect purchasing behavior that headquarters-level contacts do not see directly.
Desk research draws on national blood transfusion service reports and donor collection statistics, device clearance filings including FDA 510(k) records and EU MDR certificates for collection and apheresis systems, customs and trade data under the relevant HS codes for blood bags, tubes, and needles, and tender and procurement records published by public health systems and blood bank networks. Company filings and investor disclosures from the named suppliers provide revenue and segment detail used in the check against the bottom-up build, and industry body benchmarks from transfusion medicine associations inform regional collection volume assumptions where national statistics are incomplete.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from projected donor collection volumes, the pace at which apheresis and automated collection systems replace manual and semi-automated equipment, and pricing behavior as tender-based procurement continues to compress unit prices in mature markets even as unit volumes rise. Regulatory tightening around traceability and blood safety is treated as a step-change assumption in the markets where it is scheduled, rather than smoothed across the full period. The forecast normalizes for the temporary collection disruptions some markets recorded earlier in the historical period, so the base year reflects a resumed, more typical collection pattern rather than a depressed one.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Each segment's projected trajectory was back-tested against its own recorded 2020-2024 growth to confirm the forecast does not imply an implausible break from historical pace. Segment share shifts, including the move toward automated collection systems, were reviewed against the equipment orders and tenders reported by hospital networks and blood banks in the primary research. Sensitivities were tested on the pace of automation adoption and on tender pricing pressure, since those two assumptions move the forecast the most; the scenario range in this report reflects the outcome of that sensitivity testing rather than a fixed percentage applied uniformly across every year.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmest in the Blood Bags, Blood Collection Tubes, and Blood Transfusion figures, where donor collection statistics and device clearance records give a direct, well-disclosed base. It is weaker in the automated and apheresis-based technology split and in several emerging Asia Pacific and Middle East and Africa country figures, where installed-base data is thinner and collection statistics are reported less consistently. A structural risk that would force a revision is a faster-than-assumed shift away from manual collection methods in markets that currently rely on them, which would pull share into the automated segment sooner than modeled here.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Blood Processing Devices Market projected to reach?
USD 99.2 Billion by 2034, CAGR 7.01%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 37% of global revenue through 2034.
05Which segment leads the market?
Blood Bags is the largest line by Product, at 30% of revenue in 2025.
06Who are the key companies profiled?
Abbott (US), Biomerieux (France), BD(US), Bio-Rad Laboratories. Inc (US), Danaher (US), Grifols S.A (India), Thermogenesis Holdings. Inc (US), Terumo Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Haemonetics Corporation (US). Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.